Literature DB >> 346201

Fever and infection in leukemic patients: a study of 494 consecutive patients.

G P Bodey, V Rodriguez, H Y Chang.   

Abstract

All of the febrile episodes occurring in 494 adults with acute leukemia were reviewed. There were an average of 2.39 febrile episodes per patient and the patients spent 28% of their days in the hospital with fever. Sixty-four percent of the febrile episodes were due to infection. The most common types of infection were disseminated infection and pneumonia, which together accounted for 69% of the total episodes of documented infection. The etiologic agent was identified in 73% of the documented infections and gram-negative bacilli were responsible for the great majority. The most common gram-negative bacilli causing infection were Escherichia coli, Klebsiella spp. and Pseudomonas aeruginosa. During the course of their leukemia, 31% of the patients had repeated episodes of infection caused by the same organism and 13% ahd repeated FUO's. Fever occurred most often when the patients had neutropenia (less than 500/mm3). The fatality rate from septicemia decreased from 84% in 1966 to 44% in 1972. The fatality rate for major infections caused by gram-positive cocci was 16%, for gram-negative bacilli was 37% and for fungi was 86%. Although infection remains a serious problem in leukemia patients, considerable progress has been made.

Entities:  

Mesh:

Year:  1978        PMID: 346201     DOI: 10.1002/1097-0142(197804)41:4<1610::aid-cncr2820410452>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  49 in total

Review 1.  Antifungal treatment strategy in leukemia patients.

Authors:  T Büchner; N Roos
Journal:  Ann Hematol       Date:  1992-10       Impact factor: 3.673

2.  Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes.

Authors:  Sarah A Buckley; Megan Othus; Vladimir Vainstein; Janis L Abkowitz; Elihu H Estey; Roland B Walter
Journal:  Am J Hematol       Date:  2014-02-24       Impact factor: 10.047

3.  Neutrophil count in African Americans: lowering the target cutoff to initiate or resume chemotherapy?

Authors:  Matthew M Hsieh; John F Tisdale; Griffin P Rodgers; Neal S Young; Edward L Trimble; Richard F Little
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

4.  Development of a chromosomal DNA probe for the laboratory diagnosis of aspergillosis.

Authors:  M A Gabal
Journal:  Mycopathologia       Date:  1989-05       Impact factor: 2.574

5.  Protective effect of human granulocyte colony-stimulating factor on microbial infection in neutropenic mice.

Authors:  M Matsumoto; S Matsubara; T Matsuno; M Tamura; K Hattori; H Nomura; M Ono; T Yokota
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

6.  Economic analysis of filgrastim use for patients with acute myeloid leukaemia in the UK: a comparison of collection methods of resource use data.

Authors:  Bo Standaert; Janet Goldstone; Z John Lu; Moshe Haim Erder; John Liu Yin
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

7.  [Development of the risk of infection in the child with leukemia].

Authors:  P Lutz; G Delage; G E Rivard; G Berdnikoff
Journal:  Can Med Assoc J       Date:  1983-09-01       Impact factor: 8.262

8.  Serratia infections in patients with neutropenia.

Authors:  F Hartmann; T Gheorghiu; H Leupold; F Baer; V Diehl
Journal:  Klin Wochenschr       Date:  1991-08-01

9.  Therapeutic activities of cefazolin, cefotaxime, and ceftazidime against experimentally induced Klebsiella pneumoniae pneumonia in rats.

Authors:  I A Bakker-Woudenberg; J C van den Berg; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

10.  Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases.

Authors:  W Kern; E Kurrle; T Schmeiser
Journal:  Infection       Date:  1990 May-Jun       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.